In a groundbreaking achievement for the biotechnology industry, Dyno Therapeutics has announced the formal launch of its cutting-edge agentic AI system called Dyno Psi-Phi (pronounced “sci-fi”) for protein binder design at the NVIDIA GTC 2026 conference. The groundbreaking technology, developed through a strategic partnership with NVIDIA, is geared towards overcoming the major hurdle of linking computational and experimental results through high-performance computing. The suite is anchored by two primary components: Dyno Phi, a set of experimentally grounded filters that predict the success of protein designs in wet-lab settings, and Dyno Psi-1, an open-weight generative model trained on NVIDIA’s DGX Cloud that prioritizes structural diversity and controllability. By integrating these tools with NVIDIA’s BioNeMo and offering programmatic access via REST APIs and Claude Code skills, Dyno is democratizing the ability to create sequence-based medicines.
Also Read: Loopback Analytics and Cornerstone AI Forge Strategic Alliance to Standardize LOINC Data, Accelerate Pharma Insights and Improve Patient Care
As Sam Sinai, Ph.D., Head of Machine Learning and Cofounder at Dyno Therapeutics, explained, “Dyno’s Psi-Phi design suite is a step toward solving a major challenge in modern AI: connecting in silico benchmarks to real-world outcomes.” He further noted that while existing computational filters are effective, they often limit exploration, whereas Psi-Phi introduces models that “pair naturally with high-throughput experiments, so designs succeed not just at binding, but across downstream requirements.” Supporting this vision, Eric Kelsic, Ph.D., CEO and Cofounder, emphasized that “Our collaboration with NVIDIA opens a new world of extraordinary AI leverage for Dyno’s partners, making frontier AI accessible to an even broader community of therapeutic developers,” ultimately enabling the more confident creation of effective medicines for genetic diseases. This launch represents a significant leap forward in “Genetic Agency,” providing developers with the advanced infrastructure and agentic interfaces necessary to scale complex molecular design and accelerate the journey from digital concept to life-saving patient treatment.
